Quest Diagnostics Falls 6.9% While AnaptysBio Rises 5.6%
Quest Diagnostics shares dropped 6.9% after the close, while AnaptysBio gained 5.6% following its Q2 earnings release.
Key points
- Quest Diagnostics shares fell 6.9% to $228.00 in after-hours trading, leading a group of declining health care stocks.
- AnaptysBio rose 5.62% to $58.01 following the release of its second-quarter earnings, boosting its $1.6 billion valuation.
- Milestone Scientific gained 11.8% to $0.44, while CytoMed Therapeutics dropped 15.4% to $0.82, showing high volatility in small caps.
Health care stocks experienced significant price volatility in Monday's after-hours trading, with Quest Diagnostics leading the decliners. The diagnostic company, valued at $27.2 billion, saw its shares drop 6.9% to $228.00. This movement contrasts sharply with AnaptysBio, which rose 5.62% to $58.01, a gain attributed to the release of its second-quarter earnings.
According to data reported by Benzinga, several small-cap biotech firms also posted gains. Milestone Scientific climbed 11.8% to $0.44, and Evotec increased 8.44% to $1.67. These moves occurred without specific earnings announcements cited in the immediate feed, highlighting broader sector sentiment shifts alongside individual company news.
Quest Diagnostics Leads Decliners
Quest Diagnostics recorded the largest percentage decline among major players, falling to $228.00. The company’s market capitalization remains substantial at $27.2 billion. Other notable losers included CytoMed Therapeutics, which dropped 15.4% to $0.82, and Beyond Air, which fell 7.35% to $2.90. Mira Pharmaceuticals also declined 6.69% to $0.82, reflecting broader weakness in smaller diagnostic and therapeutic firms.
Biotech Firms Post Strong Gains
AnaptysBio, with a market cap of $1.6 billion, was the primary driver of upward movement in the large-cap segment. Its 5.62% rise to $58.01 followed the publication of its Q2 financial results. Smaller competitors followed suit; Universe Pharmaceuticals gained 6.46% to $4.94, and NovaBridge Biosciences increased 6.21% to $1.71. Creative Medical Tech also rose 5.47% to $1.06, indicating sustained interest in niche medical technology providers.
Market Cap Variations Highlight Risk
The session underscored the disparity in valuation stability across the sector. While Quest Diagnostics maintains a $27.2 billion valuation, firms like Silexion Therapeutics operate with a market cap of just $2.4 million. Silexion shares fell 6.07% to $0.51, mirroring the 6.07% drop seen in iTonic Holdings to $0.31. These micro-cap stocks exhibit higher volatility, with price swings often exceeding those of established industry leaders.
